Zhiming Li

West China School of Public Health and West China Fourth Hospital, Sichuan University

Affiliated withSichuan University

Research Area

Biography

Zhiming Li has not added Biography.
If you are Zhiming Li and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. Journal of hematology & oncology\| PubMed ID: 28298231	2017
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. Frontiers in oncology\| PubMed ID: 34804937	2021
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study. Cancer medicine\| PubMed ID: 35438258	2022
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. The Lancet. Haematology\| PubMed ID: 35772429	2022
Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China. Cancer medicine\| PubMed ID: 36106610	2023
The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 36735519	2023
A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell l... American journal of hematology\| PubMed ID: 36970971	2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. Blood advances\| PubMed ID: 37078706	2023
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. American journal of hematology\| PubMed ID: 37647123	2023
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 38190117	2024
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia\| PubMed ID: 38378844	2024
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis. British journal of haematology\| PubMed ID: 39327747	2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial. Journal for immunotherapy of cancer\| PubMed ID: 39455094	2024
Editorial: Epigenetic regulation of genome integrity and its implications in human diseases. Frontiers in cell and developmental biology\| PubMed ID: 39720006	2024
A tale of two strands: Decoding chromatin replication through strand-specific sequencing. Molecular cell\| PubMed ID: 39824166	2025
Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study. Oral oncology\| PubMed ID: 39952083	2025
Multimodal Masked Autoencoder Based on Adaptive Masking for Vitiligo Stage Classification. Journal of imaging informatics in medicine\| PubMed ID: 40301294	2025